Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the Prospective ABCSG-12 Trial Full Text
Journal of Clinical Oncology, 05/17/2011
Clinical Article
Pfeiler G et al. – BMI significantly impacts on the efficacy of anastrozole plus goserelin in premenopausal patients with breast cancer, probably through influencing aromatase availability and/or ovarian suppression by goserelin.
Methods- ABCSG-12 examined the efficacy of ovarian suppression using goserelin (3.6 mg subcutaneously every 28 days) in combination with anastrozole or tamoxifen with or without zoledronic acid (4 mg intravenously every 6 months) in premenopausal women with endocrine-responsive breast cancer
- BMI calculated using prospectively collected data on patients' height and weight at study entry
- BMI categories have been differentiated according to WHO definition
- Overweight patients treated with anastrozole had 60% increase in risk of disease recurrence (HR, 1.60; 95% CI, 1.06 to 2.41; P = .02) and more than a doubling in risk of death (HR, 2.14; 95% CI, 1.17 to 3.92; P = .01) compared with normal weight patients treated with anastrozole
- In overweight group, patients treated with anastrozole had nearly 50% increase in risk of disease recurrence (HR, 1.49; 95% CI, 0.93 to 2.38; P = .08) and 3-fold increase in risk of death (HR, 3.03; 95% CI, 1.35 to 6.82; P = .004) compared with patients treated with tamoxifen
